Researchers uncover that DNA changes that cause cancer drug resistance can be grouped into four categories, and identify possible new therapeutic targets.
2024
announcements
Science & Technology Using machine learning to analyse the genetic factors behind early clinical trial termination, researchers find a link between genetic evidence and trial outcome.
2024
research-highlightsscience-technology
People & Perspectives ARISE fellow Melanie Schneider shares how she uncovered a new interest in research infrastructures and supporting discovery.
2024
people-perspectivesperspectives
EMBL Announcements MSD joins as the latest partner in the Open Targets consortium, enhancing the initiative’s collaborative efforts in drug discovery.
2024
announcementsembl-announcements
Large language models are changing the way we carry out scientific data curation, annotation, and research, setting the stage for a more efficient understanding of scientific literature
2023
technology-and-innovation
Lab MattersPeople & Perspectives David Hulcoop discusses how his experience bridging organisational cultures will help address critical challenges in drug discovery and target selection at Open Targets.
2023
announcementslab-matterspeople-perspectives
EMBL AnnouncementsLab Matters Construction begins on EMBL-EBI's new building named after Janet Thornton.
2023
announcementsembl-announcementslab-matters
EMBL Announcements Coming from a pharmaceutical industry background, David Hulcoop is set to take over as Executive Director of the public-private partnership Open Targets.
2023
announcementsembl-announcements
Science & Technology A new tool for the interpretation of missense variation in humans – ProtVar – will help enable drug discovery.
2023
sciencescience-technologytechnology-and-innovation
Researchers create a network of interacting proteins – or interactome – to aid drug discovery.
2023
research-highlightsscience
Science & Technology Open Targets is using artificial intelligence and machine learning to identify and prioritise drug targets.
2023
sciencescience-technologytechnology-and-innovation
Open Targets announces that Genentech will become the seventh partner in the drug discovery and validation consortium.
2022
announcementsscience
Connections Open Targets, a consortium focused on drug target identification, prioritisation, and validation, announced today that Pfizer has joined as a partner.
2022
announcementsconnectionsscience
Lab MattersPeople & Perspectives Ian Dunham walks us through his career so far including working on the human genome project, seeing his work on the cover of Nature and his current role as Director of Open Targets.
2021
lab-matterspeople-perspectives
Science & Technology Researchers establish a framework for identifying new drugs capable of exploiting a cell’s own machinery.
2021
sciencescience-technology
Lab MattersPeople & Perspectives Open Targets welcomes new Informatics Science Director
2020
lab-matterspeople-perspectives
Science & Technology How computer processing of human language is harnessed by EMBL scientists
2019
sciencescience-technology
Lab Matters Reflecting on 20 years of EMBLEM
2019
lab-matters
Lab MattersPeople & Perspectives New director drives drug discovery partnership forward
2019
lab-matterspeople-perspectives
No matching posts found
Looking for past print editions of EMBLetc.? Browse our archive, going back 20 years.
EMBLetc. archive
